SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.

View in: PubMed

subject areas

Adamantane
AMP-Activated Protein Kinases
Animals
Apoptosis
Benzhydryl Compounds
CARD Signaling Adaptor Proteins
Cells, Cultured
Diabetes Mellitus, Type 2
Diabetic Cardiomyopathies
Dipeptides
Dipeptidyl Peptidase 4
Dipeptidyl-Peptidase IV Inhibitors
Disease Models, Animal
Drug Therapy, Combination
Fibroblasts
Fibrosis
Glucosides
Hypoglycemic Agents
Inflammasomes
Inflammation Mediators
Kidney Tubules, Proximal
Male
Mice, Inbred C57BL
Mice, Obese
Myocytes, Cardiac
NLR Family, Pyrin Domain-Containing 3 Protein
Signal Transduction
Sodium-Glucose Transporter 2
Stroke Volume
Time Factors
Ventricular Function, Left

authors with profiles

MANDEEP BAJAJ
YOCHAI BIRNBAUM